Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907)

Publisher： Karger

E-ISSN： 1423-0232|89|3|143-151

ISSN： 0030-2414

Source： Oncology, Vol.89, Iss.3, 2015-04, pp. : 143-151

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prospective Phase II Study of Neoadjuvant Therapy with Cisplatin, 5-Fluorouracil, and Bevacizumab for Locally Advanced Resectable Esophageal Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 7-8, 2012-07 ,pp. : 427-431

Karger

Access to resources Recommend Favorite

Overall Survival with Cisplatin and 5-Fluorouracil Neoadjuvant Treatment in Patients with Esophageal Cancer: Single-Center Experience

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 673-677

Karger

Access to resources Recommend Favorite

Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer

By  

Oncology, Vol. 92, Iss. 2, 2016-12 ,pp. : 101-108

Karger

Access to resources Recommend Favorite

Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer

By  

Oncology, Vol. 93, Iss. 1, 2017-04 ,pp. : 36-42

Karger

Access to resources Recommend Favorite

Neoadjuvant Chemotherapy with Sequential Methotrexate and 5-Fluorouracil Scheduling, Epirubicin and Cisplatin for Locally Advanced Bladder Cancer

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 1-5

Karger

Access to resources Recommend Favorite